- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04112199
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Terlipressin has been shown to reduce portal hypertension, improve renal function and induce natriuresis in cirrhotic patients with ascites without hepatorenal syndrome (HRS). It is approved in Europe for the treatment of bleeding esophageal varices and HRS type 1 and is usually administered as an IV bolus starting at 1 mg every 6 h and increased to 2 mg every 6 h (maximum 8 mg/day depending on response).
This study will evaluate the use of terlipressin delivered by continuous infusion for two 28 day treatment cycles for reduction of ascites accumulation and complications in adult patients with refractory ascites secondary to decompensated cirrhosis. Continuous infusion allows for a significant reduction in the daily effective dose required for treatment and improved safety of terlipressin delivered as a low-dose continuous infusion could enable its use in the outpatient setting in the prolonged treatment of patients with refractory ascites.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Jacksonville
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Maryland
-
Baltimore, Maryland, United States, 21202
- Mercy Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire Veterans Affairs Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Informed consent prior to any study-related procedures
- Male or female patients age 18 to 75 years old
- Cirrhosis of the liver (Non-alcoholic steatohepatitis, alcohol, viral and autoimmune)
Patient has diuretic-resistant, intractable ascites or is unsuitable for treatment with diuretics and required:
o In the 60-day period from the last LVP before consent, required, between 3 and 9 LVPs, including the last LVP on or before the day of consent.
- Dates for all LVPs that occurred within 90 days prior to consent have been recorded. The volume of ascites removed at each of the LVPs must also have been recorded for the 90-day period prior to the last LVPs before consent
- Serum creatinine (SCr) ≤2.00 mg/dL determined prior to randomization
- Women of child-bearing potential (e.g. not post-menopausal for at least one year or surgically sterile) must be neither pregnant nor lactating and must agree to use adequate birth control or be abstinent for the duration of the study
- If patient is treated with ACE inhibitors or beta blockers, dose has been stable for at least 30 days prior to randomization and may be maintained on that dose for the trial duration
- If patient is treated with diuretics, patient has been on a stable daily dose for at least 10 days prior to consent
- Willing and able to comply with trial instructions
Exclusion Criteria
- Ascites with causes other than cirrhosis; such as cardiac or nephrogenic ascites or malignant ascites due to peritoneal carcinomatosis
- Urinary sodium excretion >100 mmol/day between day of consent and randomization
- Total bilirubin >5 mg/dL
- Blood clotting International normalized ratio (INR) >2.5
- Current or recent (within 3 months of consent) renal replacement therapy
- Current or recent (within 3 month of consent) hepatic encephalopathy Grade 3 or 4 (West-Haven)
- Superimposed acute liver failure/injury due to factors including acute alcoholic hepatitis, acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning)
- History or presence of hepatic hydrothorax, known pulmonary hypertension and a history of hepatopulmonary syndrome
- Current or recent treatment (within 7 days of randomization) with octreotide, midodrine, vasopressin, dopamine or other vasopressors
- Current or recent (in the previous 60 days from consent) episode of respiratory failure requiring positive airway pressure (PAP) devices or intubation
- Sepsis episode in the previous 28 days from consent
- Episode of SBP within the 28 days prior to consent
- Episode of gastrointestinal hemorrhage (non-variceal) within 28 days prior to consent
- Episode of esophageal variceal bleed within one week prior to consent
- Ongoing documented or suspected infection
- Severe cardiovascular disease that is a contraindication to terlipressin therapy such as a history of myocardial infarction, angina pectoris, advanced arteriosclerosis, uncontrolled cardiac arrhythmia, severe coronary insufficiency or uncontrolled hypertension
- Findings suggestive of severe organic renal disease (severe proteinuria/hematuria, or abnormal renal ultrasound suggestive of obstructive renal pathology)
- Use of nephrotoxic drugs (e.g., aminoglycosides) in the 4 weeks before screening
- Severe comorbidity that in the opinion of the Investigator would affect short-term prognosis and/or disallow safe participation in the trial (such as for example, severe anemia or pancytopenia, advanced progressive neoplasia such as hepatocellular carcinoma, unless eligible for transplant)
- Patient who, in the judgment of the investigator, has been an excessive alcohol drinker in the past 12 weeks
- Patient is in the opinion of the investigator, despite previous education on sodium restriction, anticipated to remain grossly non-compliant of sodium restricted diet
- Implanted alfapump or previous recipient of alfapump that had pump removed within past 3 months
- Recipient of renal or liver transplant
- Planned elective surgery related to cirrhosis complications, for example for hernia repair
- Known allergy or hypersensitivity to terlipressin
- Participation in other clinical research studies involving the treatment with other investigational drugs or evaluation with implantable devices within 30 days of consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIV201 plus Standard of Care
BIV201 continuous infusion - treatment for two 28 day cycles.
|
BIV201 continuous infusion with terlipressin for a total of two 28 day cycles.
Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
Other Names:
|
No Intervention: Standard of care
Per AASLD guidelines: diuretics and therapeutic paracentesis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of complications, at least grade 2 severity
Time Frame: 180 days following randomization
|
Incidence of complications, at least grade 2, during the 180 days following randomization
|
180 days following randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cumulative ascites
Time Frame: 12 weeks
|
Change in cumulative ascites during the first 12 weeks following randomization versus the 12 weeks pre-treatment
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Joseph Palumbo, MD, BioVie Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIT-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Decompensated Cirrhosis
-
Region StockholmSahlgrenska University Hospital, SwedenRecruitingHemostasis in Decompensated Liver Cirrhosis | Inflammation in Decompensated Liver CirrhosisSweden
-
University College, LondonLondon School of Hygiene and Tropical Medicine; CyberLiver LtdRecruitingDecompensated CirrhosisUnited Kingdom
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Beijing 302 HospitalVCANBIO Cell & Gene Engineering Corporation, LtdRecruitingDecompensated CirrhosisChina
-
Beijing 302 HospitalLanZhou University; Chinese PLA General Hospital; Renmin Hospital of Wuhan University and other collaboratorsNot yet recruitingDecompensated CirrhosisChina
-
Chinese Academy of SciencesThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...UnknownDecompensated CirrhosisChina
-
Zagazig UniversityCompletedDecompensated Cirrhosis
-
Institute of Liver and Biliary Sciences, IndiaUnknown
-
Shandong Qilu Stem Cells Engineering Co., Ltd.First Affiliated Hospital of Fujian Medical University; Shanghai Public Health... and other collaboratorsUnknownDecompensated Liver Cirrhosis
-
Medical University of GrazActive, not recruitingDecompensated CirrhosisAustria
Clinical Trials on BIV201 continuous infusion
-
Mongi Slim HospitalCompletedEpidural; AnalgesiaTunisia
-
Dompé Farmaceutici S.p.ACompletedKidney Diseases | Ischemia-Reperfusion InjuryUnited States, France, Italy, Spain
-
Hospital Universitario San IgnacioWithdrawnCritical Illness | Enteral Feeding Intolerance | Nutrition SupportColombia
-
University of Sao PauloUnknownSepsis | Gram-Positive Bacterial Infections | NephrotoxicityBrazil
-
University of California, San DiegoCompletedBreast Cancer | Mastectomy | Paravertebral Catheter InsertionUnited States
-
The George InstituteNational Health and Medical Research Council, Australia; Australian and New...CompletedSepsisBelgium, Australia, United Kingdom, New Zealand, France, Malaysia, Sweden
-
Milton S. Hershey Medical CenterWithdrawnSurgical Site Infections
-
University of VirginiaThe University of QueenslandCompletedPlasma Concentration of AntibioticsUnited States
-
Texas Tech University Health Sciences Center, El...Texas Tech University Health Sciences CenterTerminatedAnalgesia in Total Knee ArthroplastyUnited States
-
The AlfredUnknown